At a glance
ClinicalIndex Comparison Record- ✓Newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, WHO II or III
- ✓Stage III-IVa (except T3-4N0) by 8th edition AJCC
- ✓No distant metastasis (M0)
- ✓Age 18-65 years
- ✕Keratinizing nasopharyngeal carcinoma (WHO I)
- ✕Age <18 or >65 years
- ✕Palliative intent treatment
- ✕Prior malignancy except skin cancer or in situ cervical cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Nedaplatin Versus Cisplatin in Induction Chemotherapy Combined With Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma：a Prospective, Parallel, Randomized, Open Labeled, Phase III Non-Inferiority Clinical Study
In Brief
A Phase 3 clinical trial evaluating Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, and 3 other interventions for Nasopharyngeal Carcinoma. Currently recruiting, targeting 352 participants across 1 site.
Detailed Summary
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Study Details
Timeline
Interventions
Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.